DecisionView Announces Availability of Software-as-a-Service Offering
Posted on: Wednesday, 30 September 2009, 10:00 CDT
SAN FRANCISCO, Sept. 30 /PRNewswire/ -- DecisionView, Inc., the leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the immediate availability of the Software-as-a-Service (SaaS) version of StudyOptimizer, the company's flagship solution. Under the new model, DecisionView will provide hosting, implementation, and support of StudyOptimizer on a pay-as-you-go basis that is available for individual trials.
"It is not uncommon for life sciences companies to experience enrollment delays in one or more critical studies. In cases like these, the need for an application like StudyOptimizer becomes significant," said Jim Scullion, CEO of DecisionView. "We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible. With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter timeframe, even on a single trial."
Hosted in a SAS70 certified infrastructure that provides robust security and privacy features, the new model is designed to deliver a lower cost of ownership and rapid deployment of StudyOptimizer on any number of studies, providing study managers, recruitment planners, and other personnel managing the enrollment process with a fast way to access DecisionView's world-class enrollment planning capabilities.
Designed for organizations conducting clinical trials, StudyOptimizer is a global collaborative solution which fosters best practices and automates the clinical enrollment process by integrating a robust forecasting model, rich visualizations, and enrollment planning capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.
About DecisionView
DecisionView develops innovative Web-based software solutions that enable life sciences organizations around the world to improve patient enrollment in clinical trials. DecisionView improves the visibility and predictability of enrollment performance by embedding predictive analytics and scenario modeling capabilities that deliver proven business value, including faster cycle times and reducing clinical trials costs. Granite Ventures, Adobe Ventures, and Aeris Capital are primary investors in the company.
For additional information, visit www.decisionview.com.
SOURCE DecisionView
Source: PR Newswire
Related Articles
- Fujirebio Diagnostics Named Life Sciences Company of the Year
- 6Connex Announces Strategic Partnerships With Key Healthcare and Life Sciences Companies
- Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies
- Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies
- Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore
- OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
- Kane Biotech Has Been Selected As One of Canada's Top 10(TM) Emerging Life Sciences Companies
- Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
- RCM Technologies, Inc. Announces Release of Validation 2.0 Solution for Life Sciences Companies
- RxKinetix Receives University of Colorado Technology Transfer Life Sciences Company of the Year Award
User Comments (0)

RSS Feeds